PHARMACEUTICALS News - Blockchain.News

DEEPSEEK

DeepSeek is an AI company and a family of large language models based in Hangzhou, China. It was founded in 2023 and funded by High-Flyer, a well - known quantitative asset management giant. DeepSeek is dedicated to developing advanced large language models and related technologies. It has released several models, including DeepSeek LLM, DeepSeek Coder, DeepSeekMath, and DeepSeek - VL. The latest version, DeepSeek - V3, which was launched in December 2024, has 67.1 billion parameters and was trained on a dataset of 14.8 trillion tokens. It uses FP8 training and open - sources the native FP8 weights. Benchmark tests show that it outperforms Llama 3.1 and Qwen 2.5 while matching GPT - 4O and Claude 3.5 Sonnet. In addition, DeepSeek - R1, which was officially released on January 20, 2025, performs on a par with OpenAI O1 in terms of mathematics, code, and natural language reasoning tasks. DeepSeek's models have a wide range of applications, such as chat and coding scenarios, multilingual automatic translation, image generation, and AI painting. With their high performance and low cost, DeepSeek's models have quickly gained popularity. For example, on February 2, 2025, the DeepSeek app climbed to the top of the download charts in 140 countries on the Apple App Store and also topped the Android Play Store in the United States

deepseek

IQVIA and NVIDIA Collaborate to Enhance Clinical Trials with AI Innovations

IQVIA and NVIDIA introduce AI orchestrator agents to streamline clinical trials and drug commercialization, aiming to accelerate the delivery of therapies to patients.

by Luisa Crawford
Jun 11, 2025

deepseek

NVIDIA's NIM Agent Blueprint Transforms Drug Discovery with AI-Driven Virtual Screening

NVIDIA's NIM Agent Blueprint leverages generative AI for faster, cost-effective drug discovery, enhancing hit-to-lead transitions.

by Terrill Dicki
Aug 27, 2024

DEEPSEEK

IQVIA and NVIDIA Collaborate to Enhance Clinical Trials with AI Innovations

NVIDIA's NIM Agent Blueprint Transforms Drug Discovery with AI-Driven Virtual Screening

Trending topics